Inactive Instrument

Akcea Therapeutics, Inc.

AKCA

US00972L1070

Akcea Appoints Kia Motesharei as New Senior Vice President, Business Development and Corporate Strategy

June 09, 2020 at 12:00 pm

Akcea Therapeutics, Inc. announced that Kia Motesharei, Ph.D., has joined the company as Senior Vice President of Business Development & Corporate Strategy. In this role Dr. Motesharei will drive business development activities at Akcea as well as continue to enhance the corporate strategy in conjunction with the Akcea leadership team.

Latest news about Akcea Therapeutics, Inc.

Aspen Neuroscience, Inc. Appoints Lisa Johnson-Pratt as Senior Vice President, Therapeutic Program Lead	02-14	CI
Mersana Therapeutics, Inc. Announces Carla Poulson as Chief Human Resources Officer	19/01/21	CI
Akcea Therapeutics Announces Scottish Medicines Consortium Enabled Access to Volanesorsen on the National Health Service in Scotland for the Treatment of Familial Chylomicronaemia Syndrome	09/11/20	CI
Akcea Therapeutics, Inc. Announces Management Changes	13/10/20	CI
Akcea Therapeutics, Inc.(NasdaqGS:AKCA) dropped from S&P TMI Index	12/10/20	CI
Akcea Therapeutics, Inc.(NasdaqGS:AKCA) dropped from S&P Global BMI Index	12/10/20	CI
Akcea Therapeutics, Inc.(NasdaqGM:AKCA) dropped from Russell Small Cap Comp Value Index	12/10/20	CI
Akcea Therapeutics, Inc.(NasdaqGM:AKCA) dropped from Russell 2000 Value Index	12/10/20	CI
Akcea Therapeutics, Inc.(NasdaqGM:AKCA) dropped from Russell 2500 Value Index	12/10/20	CI
Akcea Therapeutics, Inc.(NasdaqGM:AKCA) dropped from Russell 3000 Value Index	12/10/20	CI
Akcea Therapeutics, Inc.(NasdaqGM:AKCA) dropped from Russell 2000 Value-Dynamic Index	12/10/20	CI
Akcea Therapeutics, Inc.(NasdaqGM:AKCA) dropped from Russell 2500 Growth-Dynamic Index	12/10/20	CI
Akcea Therapeutics, Inc.(NasdaqGM:AKCA) dropped from Russell 2500 Value-Dynamic Index	12/10/20	CI
Akcea Therapeutics, Inc.(NasdaqGM:AKCA) dropped from Russell 3000 Index	12/10/20	CI
Akcea Therapeutics, Inc.(NasdaqGM:AKCA) dropped from Russell Small Cap Comp Growth Index	12/10/20	CI
Akcea Therapeutics, Inc.(NasdaqGM:AKCA) dropped from Russell 2000 Growth Index	12/10/20	CI
Akcea Therapeutics, Inc.(NasdaqGM:AKCA) dropped from Russell Small Cap Completeness Index	12/10/20	CI
Akcea Therapeutics, Inc.(NasdaqGM:AKCA) dropped from Russell 2000 Index	12/10/20	CI
Akcea Therapeutics, Inc.(NasdaqGM:AKCA) dropped from Russell 2500 Index	12/10/20	CI
Akcea Therapeutics, Inc.(NasdaqGM:AKCA) dropped from Russell 3000 Growth Index	12/10/20	CI
Akcea Therapeutics, Inc.(NasdaqGM:AKCA) dropped from Russell 2500 Growth Index	12/10/20	CI
Akcea Therapeutics, Inc.(NasdaqGM:AKCA) dropped from Russell 2500 Dynamic Index	12/10/20	CI
Akcea Therapeutics, Inc.(NasdaqGM:AKCA) dropped from Russell 2000 Growth-Dynamic Index	12/10/20	CI
Akcea Therapeutics, Inc.(NasdaqGM:AKCA) dropped from Russell 2000 Dynamic Index	12/10/20	CI
Ionis Pharmaceuticals, Inc. completed the acquisition of 24.23% stake in Akcea Therapeutics, Inc..	11/10/20	CI

Chart Akcea Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Akcea Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. The Company's drugs, volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx, are all based on antisense technology developed by Ionis Pharmaceuticals, Inc. (Ionis). The Company's volanesorsen drug has completed a Phase III clinical program for the treatment of familial chylomicronemia syndrome (FCS) and is currently in Phase III clinical development for the treatment of familial partial lipodystrophy (FPL). The Company's clinical pipeline contains drugs with the potential to treat inadequately addressed lipid disorders beyond elevated LDL-C that are contributing to the dramatic increase in the incidence of cardiometabolic disease, such as elevated triglycerides, oxidized phospholipids and other lipoproteins, such as lipoprotein(a), or Lp(a).

Sector

Pharmaceuticals

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+38.51%	727B
NOVO NORDISK A/S	+33.05%	599B
JOHNSON & JOHNSON	-6.23%	354B
MERCK & CO., INC.	+18.78%	328B
ABBVIE INC.	+1.35%	277B
ASTRAZENECA PLC	+16.00%	243B
NOVARTIS AG	+8.09%	205B
ROCHE HOLDING AG	-5.77%	203B
AMGEN INC.	+6.19%	164B

Other Pharmaceuticals